![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Orphan-Drug Status to BioAlliance's Cancer Candidate
FDA Grants Orphan-Drug Status to BioAlliance's Cancer Candidate
The FDA has granted orphan-drug status to BioAlliance Pharma's Transdrug (doxorubicin) for the treatment of hepatocellular carcinoma, a potentially fatal form of liver cancer.
The drug employs a proprietary polymer formulated as a nanoparticle to deliver doxorubicin, a proven active cancer drug, to the site of the liver tumor via a catheter placed in the hepatic artery. Transdrug is currently completing Phase I/II clinical testing in the European Union.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct